Executive Search Success Story: Building a Scientific & Operations Team for a Cell & Gene Therapy Company

How JRG Partners executed a confidential, multi-role executive retained search strategy that equipped a global biotechnology company with the critical C-suite, clinical, and operational leadership required to advance complex cell and gene therapy programs, drive innovation, and scale global manufacturing operations.

The Challenge

A global biotechnology company focused on cell and gene therapies was navigating a high-stakes transition phase, advancing highly complex clinical and regulatory programs while simultaneously scaling its manufacturing capabilities. To successfully support this dual momentum, manage stakeholder scrutiny, and build institutional infrastructure, the enterprise needed to overhaul its scientific, clinical, and technical operations core. Leadership identified several critical operational and strategic pressures:

• An acute shortage of experienced, specialized cell and gene therapy executives globally
• Increasing scientific, clinical, and regulatory complexity within cell and gene therapy development pipelines
• An urgent need to scale up manufacturing capabilities for specialized advanced therapies
• Growing investor expectations and intense stakeholder scrutiny regarding development milestones
• Unaddressed succession concerns within key scientific and technical leadership positions
• High strategic demand for executive leaders explicitly able to drive innovation and operational excellence simultaneously

The enterprise determined that stabilizing its scaling operations required a synchronized corporate management structure spanning a Chief Executive Officer, Chief Scientific Officer, Chief Technical Officer, Chief Manufacturing Officer, VP Clinical Operations, VP Regulatory Affairs, VP Quality Assurance, and Head of Global Operations. Successfully executing this multi-role mandate required an executive search partner combining specialized functional vertical literacy in cell and gene processing with a track record of sourcing data-driven scientific leadership. For organizations assessing how distinct upstream research platforms scale post-market compliance architectures outside of core advanced therapies and manufacturing frameworks, a parallel analysis can be reviewed in Biotech_Executive_B_Whitelabeled.docx.

Why They Chose JRG Partners

Deep Cell & Gene Therapy Specialization

Unlike generalist recruiting agencies that lack functional immersion in intersecting biological, technical, and regulatory advanced therapy systems, JRG Partners maintains dedicated search practices spanning cell and gene therapy science, manufacturing scale-up, clinical execution, and regulatory leadership. Our consultants carry a detailed operational understanding of both life sciences compliance pipelines and specialized commercial acceleration parameters.

Real Access to Passive Talent

The most capable global clinical directors, technical officers, and scientific innovators are typically fully integrated into high-performing corporate systems, meaning they rarely monitor traditional job listings. JRG Partners bypassed conventional recruitment channels entirely, leveraging long-standing sector relationships, proprietary market intelligence, and executive networks to directly engage high-performing passive leaders invisible to standard sourcing methods.

Confidential Search Execution

Because this leadership architecture was built during an active manufacturing scale-up and high-stakes validation phase where investor confidence and proprietary scientific methodologies were at stake, absolute discretion was mandatory. JRG Partners deployed a highly secure, confidential vetting and outreach framework that successfully insulated the client’s strategic positioning, protected ongoing clinical validation metrics, and maintained total candidate trust throughout the recruitment lifecycle.

Global Sourcing Reach

Sourcing specialized manufacturing and scientific executives capable of driving global market expansion required an outreach strategy unconstrained by geographic boundaries. JRG Partners executed a coordinated talent acquisition strategy targeting top-performing leaders from cell therapy companies, gene therapy organizations, biopharmaceutical companies, contract development organizations, and clinical-stage biotech firms spanning primary international innovation hubs.

Our Corporate Search Strategy

Phase 1 — Strategic Alignment & Leadership Assessment

Our consultants partnered directly with the board of directors and executive team to map existing structural gaps, identify hidden succession risks, clarify scaling milestones, and define the exact leadership competencies required for long-term clinical and manufacturing integration. Rather than matching candidates against legacy job descriptions, we built forward-looking executive profiles dynamically tied to the enterprise’s long-term commercialization strategy.

Phase 2 — Multi-Sector Market Mapping

JRG Partners executed an exhaustive market-mapping initiative targeting process-driven clinical, regulatory, and production environments globally. Our comprehensive market map targeted key talent pools across cell therapy companies, gene therapy organizations, biopharmaceutical companies, contract development organizations, clinical-stage biotech firms, and publicly traded life sciences enterprises.

Phase 3 — Targeted Executive Engagement

Using a research-driven, highly discreet outreach framework, our consultants directly contacted and evaluated high-achieving corporate leaders with verified records of success in driving cell and gene therapy platforms. Only candidates demonstrating clear, measurable operational impact and rigorous commercial fluency advanced to the final evaluation round.

Phase 4 — Rigorous Assessment & Final Selection

Each finalist candidate underwent an extensive evaluation process looking far beyond basic professional credentials. Our consultants conversion-tested strategic and functional capabilities, international expansion agility, team-building and leadership philosophies, precision manufacturing fluency, and long-term retention potential.

Key Outcomes

• 500+ senior corporate clinical development, cell and gene research, and advanced biopharmaceutical operations executive profiles systematically mapped across North American, European, and Asian life sciences hubs.
• Successfully placed and integrated a complete executive leadership framework—spanning the CEO, Chief Scientific Officer, Chief Technical Officer, Chief Manufacturing Officer, and key vice presidents—within a tight 10-month timeline through a targeted retained search.
• Unified separate research, discovery, clinical, and manufacturing assets under a single, cohesive corporate development strategy by installing process-driven cell and gene therapy innovation leaders.
• Accelerated new-platform market validation and standardized product lifecycles by placing forward-thinking clinical operations and regulatory affairs executives.
• Mitigated long-term operational risks and optimized multi-region production frequency by placing specialized, data-driven manufacturing and quality assurance leaders.
• Protected crucial production pipelines, sensitive source architectures, and trial validation data during high-stakes growth phases through strict search confidentiality.
• Provided board directors and institutional stakeholders with a high-performance management framework explicitly equipped to eliminate regulatory barriers and drive profitable technical innovation at scale.